Published in Mol Carcinog on March 22, 2011
Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer (2012) 1.26
HBx mutants differentially affect the activation of hypoxia-inducible factor-1α in hepatocellular carcinoma. Br J Cancer (2013) 0.97
TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis (2012) 0.82
Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. World J Gastroenterol (2015) 0.81
A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines. Cancer Lett (2015) 0.78
Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res (2016) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A (1987) 8.11
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol (1996) 2.68
Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J Virol (1989) 2.21
Expression of cloned hepatitis B virus DNA in human cell cultures. Proc Natl Acad Sci U S A (1980) 2.08
Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet (1995) 1.80
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res (1995) 1.64
Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene (1999) 1.63
Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene (1993) 1.63
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol (2008) 1.53
Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int (2007) 1.38
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem (1998) 1.30
Intracellular localization of the hepatitis B virus HBx protein. J Gen Virol (2001) 1.16
Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev (2005) 1.15
Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene (2000) 1.15
Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. J Gen Virol (1997) 1.14
Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J Virol (2004) 1.12
Multiple alternate p21 transcripts are regulated by p53 in human cells. Oncogene (2006) 1.09
The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res (1997) 1.04
Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol (2006) 1.01
Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer (2010) 1.00
Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene (1997) 0.96
COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun (2008) 0.96
The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. J Biol Chem (2005) 0.95
Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol (2006) 0.89
HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX. Oncogene (1999) 0.89
Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutat Res (2004) 0.87
Partial characterization of the woodchuck tumor suppressor, p53, and its interaction with woodchuck hepatitis virus X antigen in hepatocarcinogenesis. Oncogene (1997) 0.77
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res (2006) 2.05
Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci (2010) 2.03
Translational strategies for cancer prevention in liver. Nat Rev Cancer (2003) 1.97
Public health impacts of foodborne mycotoxins. Annu Rev Food Sci Technol (2014) 1.51
Human exposure monitoring and evaluation in the Arctic: the importance of understanding exposures to the development of public health policy. Environ Health Perspect (2004) 1.45
Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A (2004) 1.45
Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat. Toxicol Sci (2009) 1.45
Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China. Cancer Prev Res (Phila) (2011) 1.37
Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem (2013) 1.31
Toxicological resources for cumulative risk: an example with hazardous air pollutants. Regul Toxicol Pharmacol (2004) 1.20
Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev (2005) 1.15
Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) (2013) 1.14
Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology (2004) 1.13
Modulation of the metabolism of airborne pollutants by glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. Carcinogenesis (2011) 1.12
Quantification of aflatoxin-B1-N7-Guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry. Chem Res Toxicol (2006) 1.10
A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res (2008) 1.06
Strategies for chemoprevention of liver cancer. Eur J Cancer Prev (2002) 1.04
Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One (2012) 1.01
Human aflatoxin albumin adducts quantitatively compared by ELISA, HPLC with fluorescence detection, and HPLC with isotope dilution mass spectrometry. Cancer Epidemiol Biomarkers Prev (2008) 1.00
Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res (2004) 0.99
Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.99
Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. Carcinogenesis (2010) 0.97
Statistical inference from multiple iTRAQ experiments without using common reference standards. J Proteome Res (2013) 0.97
Aflatoxin B1-DNA adduct formation and mutagenicity in livers of neonatal male and female B6C3F1 mice. Toxicol Sci (2011) 0.96
Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2010) 0.96
Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis (2003) 0.96
Quantification of sulforaphane mercapturic acid pathway conjugates in human urine by high-performance liquid chromatography and isotope-dilution tandem mass spectrometry. Chem Res Toxicol (2008) 0.95
Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence. Cancer Epidemiol Biomarkers Prev (2008) 0.93
DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann N Y Acad Sci (2003) 0.93
Natural chlorophyll inhibits aflatoxin B1-induced multi-organ carcinogenesis in the rat. Carcinogenesis (2007) 0.93
Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev (2005) 0.92
Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect (2011) 0.91
Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess (2011) 0.87
Urinary free bisphenol A and bisphenol A-glucuronide concentrations in newborns. J Pediatr (2013) 0.87
Quantitative analysis and chronic dosimetry of the aflatoxin B1 plasma albumin adduct Lys-AFB1 in rats by isotope dilution mass spectrometry. Chem Res Toxicol (2006) 0.87
Quantitative comparison of aflatoxin B1 serum albumin adducts in humans by isotope dilution mass spectrometry and ELISA. Cancer Epidemiol Biomarkers Prev (2006) 0.85
Urinary biomarkers of 1,3-butadiene in environmental settings using liquid chromatography isotope dilution tandem mass spectrometry. Chem Biol Interact (2006) 0.85
Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP. Cancer Epidemiol Biomarkers Prev (2002) 0.84
DNA adduct formation by 2,6-dimethyl-, 3,5-dimethyl-, and 3-ethylaniline in vivo in mice. Chem Res Toxicol (2006) 0.84
Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. Cancer Epidemiol Biomarkers Prev (2005) 0.83
Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Carcinogenesis (2013) 0.83
Formation of two novel estrogen guanine adducts and HPLC/MS detection of 4-hydroxyestradiol-N7-guanine in human urine. Chem Res Toxicol (2008) 0.82
Sulforaphane-mediated reduction of aflatoxin B₁-N⁷-guanine in rat liver DNA: impacts of strain and sex. Toxicol Sci (2011) 0.82
Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer Lett (2012) 0.81
Quantification of urinary aflatoxin B1 dialdehyde metabolites formed by aflatoxin aldehyde reductase using isotope dilution tandem mass spectrometry. Chem Res Toxicol (2008) 0.81
Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice. Toxicol Sci (2014) 0.80
A single neonatal exposure to aflatoxin b1 induces prolonged genetic damage in two loci of mouse liver. Toxicol Sci (2012) 0.80
Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry. Cancer Epidemiol Biomarkers Prev (2007) 0.80
Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis (2011) 0.80
Is it time to advance the chemoprevention of environmental carcinogenesis with microdosing trials? Cancer Prev Res (Phila) (2009) 0.79
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate. Clin Prostate Cancer (2002) 0.78
Identification of aflatoxin M1-N7-guanine in liver and urine of tree shrews and rats following administration of aflatoxin B1. Chem Res Toxicol (2003) 0.78
Prenatal exposure of mice to the human liver carcinogen aflatoxin B1 reveals a critical window of susceptibility to genetic change. Int J Cancer (2014) 0.77
Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma. Genes Chromosomes Cancer (2013) 0.77
Measurement of aflatoxin and aflatoxin metabolites in urine by liquid chromatography-tandem mass spectrometry. J Anal Toxicol (2007) 0.75
Physical/chemical/immunologic analytical methods. IARC Sci Publ (2011) 0.75